


## Claims

1. A compound of formula I or the pharmaceutically acceptable salts thereof:



5        wherein,

$R_1$  is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6;

$R_2$  is hydroxyl, sulfydryl, methylthio group, or ethylthio group at position 2, 3 or 4.

2. The compound according to claim 1, wherein  $R_1$  is methyl, and  $R_2$  is hydroxyl

10        3. The compound according to claim 1, wherein  $R_1$  is methyl at position 5, and  $R_2$  is hydroxyl at position 4.


4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof.

15        5. The pharmaceutical composition according to claim 3 comprising 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

6. A pharmaceutical composition according to claim 3, wherein the dosage form of the pharmaceutical composition is tablet, capsule, ampule or pill.


7. A method for producing the compound of formula I, comprising the steps of:

20        (a) in the presence of copper powder and anhydrous alkaline earth metal carbonate, reacting the compound of formula II and the compound of formula III at 160-200°C, thereby producing the compound of formula Ia;



wherein  $R_1$  is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6,  $R_3$  is  $-\text{OCH}_3$ ,  $-\text{SCH}_3$ ,  $-\text{OC}_2\text{H}_5$  or  $-\text{SC}_2\text{H}_5$  at position 2, 3 or 4, and X is Cl, Br or I;

- 5 (b) reacting the compound of formula Ia and  $\text{BBr}_3$  in an inert solvent at  $-10^\circ\text{C}$  to  $15^\circ\text{C}$ , thereby producing the compound of formula I:



wherein,  $R_1$  and  $R_3$  are defined as above, and  $R_2$  is  $-\text{OH}$  or  $-\text{SH}$ .

8. A method for producing a pharmaceutical composition, comprising the steps of  
 10 mixing the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 with a pharmaceutically acceptable carrier to produce a pharmaceutical composition comprising 0.01-99wt% of the compound of formula I, on the basis of the total weight.

9. Use of the compound of formula I or the pharmaceutically acceptable salts thereof  
 15 according to claim 1 in the manufacture of a medicament for preventing fibrosis.

10. A method for treating fibrosis diseases, comprising administering a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 to a subject in need thereof.